Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Central venous catheterization via the internal jugular vein (IJV) is essential for hemodialysis patients lacking viable arteriovenous access. However, repeated catheterizations can cause IJV occlusion, making reinsertion difficult and limiting future vascular options.
We retrospectively reviewed four end-stage renal disease patients with chronic right IJV occlusion in whom tunneled cuffed catheter placement was technically challenging or impossible. Percutaneous transluminal angioplasty (PTA) was performed to recanalize the occluded venous segment, followed by tunneled catheter insertion.
All patients had a history of multiple prior vascular interventions and presented with partial or complete IJV occlusion. PTA successfully restored venous patency in all cases, enabling safe tunneled cuffed catheter placement. No major procedure-related complications occurred.
PTA is a safe and effective method to restore central venous access in hemodialysis patients with IJV occlusion. This approach can preserve optimal vascular routes in patients with limited access options. Further studies are warranted to evaluate long-term patency and clinical outcomes.